Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

NCT06793371 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT06793371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Lead sponsor
Cytokinetics
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2025
Completion date
September 30, 2026
Enrollment
60 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic heart failure with preserved ejection fraction (hfpef)